Search the Newsreel

Certara, Inc. (CERT) stock price, news, quote and history

This Yahoo Finance page provides comprehensive information on Certara, Inc. (CERT), including its current stock price, historical data, and key financial metrics. It details the company's biosimulation software and services for drug discovery and development, along with performance over various periods compared to the …

ATRA DEADLINE REMINDER: Bronstein, Gewirtz & Grossman LLC Reminds

Bronstein, Gewirtz & Grossman, LLC reminds investors of Atara Biotherapeutics, Inc. (NASDAQ: ATRA) that a class action lawsuit has been filed against the company and its officers. The lawsuit alleges that Atara made misleading statements regarding manufacturing issues and the likelihood of FDA approval …

Certara Corrects EBITDA Disclosure in Earnings Presentation

Certara announced a correction to its second-quarter 2026 earnings presentation regarding the adjusted EBITDA of its recently divested Regulatory and Medical Writing business. The company clarified that the business generated approximately $23 million of adjusted EBITDA in 2025 when excluding unallocated corporate expenses, a …

Certara, Inc. (NASDAQ: CERT) corrects 2025 EBITDA for divested unit

Certara, Inc. (NASDAQ: CERT) has issued a clarification regarding the 2025 adjusted EBITDA of its recently divested Regulatory and Medical Writing business. The company initially misstated that the $17 million adjusted EBITDA figure excluded unallocated overhead costs, but now confirms it includes them. Additionally, …

Form 8K Certara Inc For: 7 August By Investing.com

This article announces the filing of a Form 8K by Certara Inc. on August 7th. It is a brief financial news item published by Investing.com, indicating a corporate event that Certara Inc. deemed important enough to report via an 8K filing. The content itself …

Certara, Inc. $CERT Shares Acquired by Quantinno Capital Management LP

Quantinno Capital Management LP significantly increased its stake in Certara, Inc. (NASDAQ:CERT) by 412.5% in the first quarter, acquiring an additional 796,007 shares. Despite this increased institutional interest, Certara missed its Q1 earnings and revenue expectations, reporting $0.08 EPS against an expected $0.09 and …

Atara Biotherapeutics, Inc. expected to post a loss of 31 cents a share - Earnings Preview

Atara Biotherapeutics, Inc. is projected to report a loss of 31 cents per share in its upcoming earnings release. This information is provided as an earnings preview by Refinitiv. The full article is available through TradingView News, which aggregates content from Reuters and other …

Atara Biotherapeutics Inc (ATRA) Earnings Forecast: Future EPS & Revenue Growth Estimates

Atara Biotherapeutics Inc (ATRA) has an earnings forecast score of 7.50, ranking 281st in the Biotechnology & Medical Research industry. Analysts have a price target of $17.00 for ATRA, with a consensus "Buy" rating based on 4 analysts. The company's expected revenue for the …

Certara (CERT) Could Be 9% Undervalued On Earnings Guidance And Buyback News

Certara, Inc. $CERT Shares Sold by Sei Investments Co.

Sei Investments Co. significantly reduced its stake in Certara, Inc. (NASDAQ:CERT) by 43.6% in the first quarter, selling 479,880 shares but retaining 620,967 shares valued at approximately $3.54 million. Despite other institutional investors increasing their holdings, Certara reported a quarterly EPS of $0.08, missing …

The Bull Case For Certara (CERT) Could Change Following Wider Q2 Loss And Leadership Shake-Up - Learn Why

In early August 2026, Certara reported second-quarter results showing slightly higher sales of US$93.27 million but a much larger net loss of US$55.27 million, alongside executive reshuffling including the departure of President and Chief Commercial Officer Leif Pedersen and the appointment of Julien Perrier …

Certara, Inc. (NASDAQ:CERT) Given Average Rating of "Hold" by Analysts

Analysts have given Certara, Inc. (NASDAQ:CERT) an average "Hold" rating, with a consensus 12-month price target of $8.95, though several brokerages recently lowered their targets. The company's recent financial results fell short of expectations, reporting quarterly EPS of $0.08 against a $0.09 consensus and …

Astrindo Nusantara (BIPI) Memacu Bisnis di Paruh Kedua

Tara Chand InfraLogistic Solutions Posts Higher Q1 Revenue but Faces Transitional Margin Pressure

Certara Announces Leadership Change in Commercial Executive Role

Certara, Inc. announced that Leif E. Pedersen has departed from his role as President and Chief Commercial Officer, effective August 1, 2026. Pedersen will remain as a Senior Advisor through December 31, 2026, to facilitate the transition, and will receive severance benefits as per …

Certara, Inc. Stock 12‑Month Price Target Cut to $7.83

Analysts have reduced the average 12-month price target for Certara, Inc. (CERT) stock from $7.93 to $7.83, with individual forecasts ranging from $6 to $9 per share. Despite the cut in the price target, the consensus rating among 13 covering analysts remains a "Buy," …

Certara Q2 2026 earnings: Software growth offsets weaker services

Certara (Nasdaq: CERT) reported Q2 2026 revenue of $93.3 million, up 1%, with diluted EPS swinging to a $0.04 loss. Software growth drove revenue, counteracting weaker services, higher operating expenses, and unfavorable currency movements that impacted GAAP profitability. The company reaffirmed its revenue outlook, …

Distribusi Voucher (DIVA) Mulai Alihkan Saham Buyback, Harga Saham Melejit

Certara (CERT) Stock Price Faces Loss Pressure Despite Software Gains

Certara's stock price declined 4.7% after its Q2 earnings report, despite a strong performance in its software segment. The company reported a net loss from continuing operations of US$6.1m, contrasting with a healthy 28.1% adjusted EBITDA margin. While software revenue increased and now constitutes …

Bronstein, Gewirtz & Grossman, LLC Encourages Certara, Inc. (CERT) Investors to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Certara, Inc. (NASDAQ:CERT) following a significant drop in its stock price. The investigation stems from Certara's Q1 2026 financial results, which reported declines in services revenue and bookings, and an …

Understanding Momentum Shifts in (ATRA)

The article analyzes momentum shifts for Atara Biotherapeutics Inc. (NASDAQ: ATRA), highlighting a near-term strong sentiment potentially challenging persistent mid and long-term weakness. It identifies a mid-channel oscillation pattern and an exceptional 233.0:1 risk-reward setup targeting a 69.2% gain versus 0.3% risk. The report …

ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit!

Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Atara Biotherapeutics, Inc. (NASDAQ:ATRA) on behalf of investors who purchased securities between May 20, 2024, and January 9, 2026. The lawsuit alleges that Atara made false or misleading statements regarding manufacturing issues …

Certara, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:CERT) 2026-08-04

This article presents the slide deck published by Certara, Inc. in conjunction with their 2026 Q2 earnings call held on August 4, 2026. The company reported Q2 EPS of $0.08, missing by $0.01, and revenue of $93.27M, a 10.81% year-over-year decrease, missing by $4.81M. …

Certara Falls Short on Q2 2026: $0.08 EPS vs $0.10 Expected

Certara, Inc. reported Q2 2026 adjusted diluted earnings per share of $0.08, missing the consensus estimate of $0.10 by 11.1%. Revenue increased modestly by 1.0% year-over-year to $93.3 million, with the Software segment showing stronger growth. The company's stock remained largely unchanged, reflecting mixed …

How Certara’s Widening Losses Amid Modest Sales Growth Will Impact Certara (CERT) Investors

Certara, Inc. (CERT) reported a significant widening of its net loss to US$55.27 million in Q2 2026, despite modest sales growth. This financial deterioration raises concerns about the company's cost discipline and the return on its R&D and AI investments, particularly given its recent …

Certara (NASDAQ:CERT) Shares Gap Down on Disappointing Earnings

Certara (NASDAQ:CERT) Posts Earnings Results, Misses Expectations By $0.01 EPS

Earnings call transcript: Certara Q2 2026 miss sends shares down 16%

Certara reported Q2 2026 adjusted earnings of $0.08 per share and revenue of $93.3 million, missing analyst expectations and causing its stock to drop 16.08%. The company noted solid software growth but weakness in services and higher costs, reaffirming its full-year guidance while emphasizing …

Certara, Inc. (CERT) Q2 Earnings and Revenues Lag Estimates

Certara, Inc. (CERT) came out with quarterly earnings of $0.08 per share, missing the Zacks Consensus Estimate of $0.1 per share. This compares to earnings of $0.07 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an …

Certara, Inc. 2026: Revenue $93.27M, EPS ($0.36) — 10-Q Summary

Certara, Inc. reported its first-quarter 2026 results, showing a 1% revenue increase to $93.27M. Despite this growth, the company experienced a significant net loss of $55.27M, or ($0.36) diluted EPS, compared to a smaller loss in the prior year. Revenue growth was primarily driven …

Certara Reports Second Quarter 2026 Financial Results

Certara Appoints Julien Perrier Chief Commercial Officer Completes previously authorized $100 million share repurchase program; Board authorizes additional $50 million under repurchase program Reaffirms 2026 revenue guidance RADNOR, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed …

Precision Trading with Certara Inc. (CERT) Risk Zones

The article provides a detailed analysis of Certara Inc. (CERT) using AI models to suggest trading strategies across different risk profiles and holding periods. It highlights a strong near-to-mid-term sentiment but a weak long-term outlook, identifying specific entry, target, and stop-loss zones for position, …

Certara Q2 Earnings Call Highlights

Key Points Interested in Certara, Inc.? Here are five stocks we like better. Q2 revenue rose 1% to $93.3 million, as 4% software growth and stronger bookings offset a 3% decline in services revenue. Software now represents 53% of the business, while services bookings …

Atara Biotherapeutics (ATRA) Projected to Release Earnings on Monday

Atara Biotherapeutics (ATRA) is expected to release its Q2 2026 earnings before market open on Monday, August 10th, with analysts projecting a loss of $0.315 per share and revenue of $0.55 million. The company's prior quarter results showed a narrower loss than estimated but …

Protara Therapeutics (TARA) Projected to Announce Quarterly Earnings on Monday

Protara Therapeutics (TARA) is expected to announce its Q2 2026 earnings before market open on Monday, August 10th, with analysts forecasting a loss of $0.3257 per share. The company previously beat estimates by $0.05. Despite a stock decline, TARA holds a "Moderate Buy" consensus …

Certara Q2 2026 Earnings Preview

* Certara (CERT [https://seekingalpha.com/symbol/CERT]) is scheduled to announce Q2 earnings results on Tuesday, August 4th, before market open. * The consensus EPS Estimate is $0.09 [https://seekingalpha.com/symbol/CERT/earnings/estimates] (+28.6% Y/Y) and the consensus Revenue Estimate is $98.08M (-6.2% Y/Y). * Over the last 2 years, CERT …